JP2017521486A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017521486A5 JP2017521486A5 JP2017516251A JP2017516251A JP2017521486A5 JP 2017521486 A5 JP2017521486 A5 JP 2017521486A5 JP 2017516251 A JP2017516251 A JP 2017516251A JP 2017516251 A JP2017516251 A JP 2017516251A JP 2017521486 A5 JP2017521486 A5 JP 2017521486A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- peptide
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462007159P | 2014-06-03 | 2014-06-03 | |
| US62/007,159 | 2014-06-03 | ||
| PCT/US2015/033509 WO2015187540A1 (en) | 2014-06-03 | 2015-06-01 | Peptide-drug conjugates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019107602A Division JP2019189623A (ja) | 2014-06-03 | 2019-06-10 | ペプチド−薬物複合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017521486A JP2017521486A (ja) | 2017-08-03 |
| JP2017521486A5 true JP2017521486A5 (cg-RX-API-DMAC7.html) | 2018-12-20 |
| JP6539729B2 JP6539729B2 (ja) | 2019-07-03 |
Family
ID=54700553
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017516251A Active JP6539729B2 (ja) | 2014-06-03 | 2015-06-01 | ペプチド−薬物複合体 |
| JP2019107602A Pending JP2019189623A (ja) | 2014-06-03 | 2019-06-10 | ペプチド−薬物複合体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019107602A Pending JP2019189623A (ja) | 2014-06-03 | 2019-06-10 | ペプチド−薬物複合体 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9579317B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3152223B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6539729B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN106456799B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015270924B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2951049C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2857192T3 (cg-RX-API-DMAC7.html) |
| MA (1) | MA40030A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015187540A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6854759B2 (ja) * | 2014-08-22 | 2021-04-07 | ヤフェイ シャンハイ バイオログ メディスン サイエンス アンド テクノロジー カンパニー リミテッド | 腫瘍微環境によって特異的活性化する小分子標的結合体およびその使用 |
| MX2018011627A (es) * | 2016-03-24 | 2019-01-10 | Bayer Pharma AG | Profarmacos de farmacos citotoxicos que tienen grupos enzimaticamente escindibles. |
| CN107375288B (zh) | 2016-05-16 | 2019-08-23 | 博瑞生物医药（苏州）股份有限公司 | 多臂的聚合靶向抗癌偶联物 |
| KR20190099250A (ko) | 2016-12-21 | 2019-08-26 | 바이엘 악티엔게젤샤프트 | 효소적으로 절단가능한 기를 갖는 세포독성 활성제의 전구약물 |
| CN108314703B (zh) * | 2017-01-17 | 2022-02-01 | 亚飞（上海）生物医药科技有限公司 | 分子定点靶向和激活的激酶抑制剂的制备和用途 |
| US11191843B2 (en) | 2017-04-21 | 2021-12-07 | Brightgene Bio-Medical Technology Co., Ltd. | Multi-arm targeting anti-cancer conjugate |
| CN107670048B (zh) | 2017-08-30 | 2019-04-26 | 南京明臻医药科技有限公司 | 具有协同抗癌活性的中间体药物和聚乙二醇偶联协同抗癌药物、及其制备方法和应用 |
| JP2022516574A (ja) * | 2019-01-07 | 2022-02-28 | センナ バイオサイエンシーズ インク． | 新規ペプチドとその使用 |
| SG11202110436UA (en) * | 2019-04-05 | 2021-10-28 | Prolynx Llc | Improved conjugation linkers |
| US20220313625A1 (en) * | 2019-05-24 | 2022-10-06 | The Jikei University | Pharmaceutical agent, medicinal solution for cleaning pulmonary alveoli, and nebulizer |
| WO2022094237A1 (en) * | 2020-10-30 | 2022-05-05 | Avacta Life Sciences Limited | Enzyme activated serum extended half-life therapeutic conjugates |
| EP4237012A1 (en) * | 2020-10-30 | 2023-09-06 | Avacta Life Sciences Limited | Fap-activated serum extended half-life therapeutic conjugates |
| CN115850288B (zh) * | 2022-11-25 | 2025-03-21 | 中科帅天医药(深圳)有限公司 | 一种丝裂霉素c前体药物及其制备方法和应用 |
| IL322909A (en) * | 2023-03-09 | 2025-10-01 | Bicycletx Ltd | Synthesis of bicyclic toxin conjugates and their intermediates |
| CN117683079B (zh) * | 2023-12-12 | 2025-04-04 | 九洲药业(杭州)有限公司 | 一种抗体偶联药物连接子的固相合成方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3803223A (en) * | 1970-07-20 | 1974-04-09 | Searle & Co | 3-amino-n-substituted succinamic acids and intermediates thereto |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| CA2399255A1 (en) * | 2000-02-24 | 2001-08-30 | Genentech, Inc. | Caspase activated prodrugs therapy |
| US8314060B2 (en) | 2000-09-05 | 2012-11-20 | Biosight Ltd. | Peptide conjugated anti-cancer prodrugs |
| EP1635858A4 (en) | 2003-05-29 | 2009-08-26 | Scripps Research Inst | TARGETED DELIVERY TO LEGUMAIN EXPRESSING CELLS |
| EP1976861A2 (en) * | 2005-11-29 | 2008-10-08 | The Scripps Research Institute | Inhibiting tumour cell invasion, metastasis and angiogenesis through targetting legumain |
| EP2266964B1 (en) * | 2009-06-22 | 2013-01-09 | KTB Tumorforschungsgesellschaft mbH | Acid-labile trigger units |
| US8394922B2 (en) * | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
| US20140057844A1 (en) | 2010-12-03 | 2014-02-27 | Tin Tin Su | Chemical entities and therapeutic uses thereof |
-
2015
- 2015-06-01 WO PCT/US2015/033509 patent/WO2015187540A1/en not_active Ceased
- 2015-06-01 MA MA040030A patent/MA40030A/fr unknown
- 2015-06-01 CN CN201580029854.5A patent/CN106456799B/zh active Active
- 2015-06-01 JP JP2017516251A patent/JP6539729B2/ja active Active
- 2015-06-01 EP EP15803150.0A patent/EP3152223B1/en active Active
- 2015-06-01 CA CA2951049A patent/CA2951049C/en active Active
- 2015-06-01 ES ES15803150T patent/ES2857192T3/es active Active
- 2015-06-01 US US14/726,897 patent/US9579317B2/en active Active
- 2015-06-01 AU AU2015270924A patent/AU2015270924B2/en active Active
-
2017
- 2017-01-27 US US15/417,615 patent/US20170232023A1/en not_active Abandoned
-
2019
- 2019-06-10 JP JP2019107602A patent/JP2019189623A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017521486A5 (cg-RX-API-DMAC7.html) | ||
| Araste et al. | Peptide-based targeted therapeutics: Focus on cancer treatment | |
| JP2019501204A5 (cg-RX-API-DMAC7.html) | ||
| JP2017171685A5 (cg-RX-API-DMAC7.html) | ||
| NZ601818A (en) | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers | |
| JP2011079858A5 (cg-RX-API-DMAC7.html) | ||
| JP2018502120A5 (cg-RX-API-DMAC7.html) | ||
| EP2301531A3 (en) | Combinations and modes of administration of therapeutic agents and combination therapy | |
| JP2018503668A5 (cg-RX-API-DMAC7.html) | ||
| JP2015520753A5 (cg-RX-API-DMAC7.html) | ||
| JP2021505661A5 (cg-RX-API-DMAC7.html) | ||
| WO2005072061A3 (en) | Conjugates for cancer therapy and diagnosis | |
| EA201890146A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ | |
| WO2016004048A3 (en) | Targeted conjugates and particles and formulations thereof | |
| JP2015502926A5 (cg-RX-API-DMAC7.html) | ||
| JP2017523184A5 (cg-RX-API-DMAC7.html) | ||
| WO2015097621A3 (en) | Pharmaceutical combinations | |
| JP2017530184A5 (cg-RX-API-DMAC7.html) | ||
| FI3511004T3 (fi) | Yhdistelmävalmisteita syövän hoitoon | |
| SA521421371B1 (ar) | لقاحات الببتيد | |
| EA201101651A1 (ru) | Непрерывное введение интегриновых лигандов для лечения рака | |
| JP2016526021A5 (cg-RX-API-DMAC7.html) | ||
| RU2020102713A (ru) | Применение изовалерил-спирамицина i, ii и/или iii при изготовлении препарата для лечения и/или профилактики опухоли и получения лекарственного препарата | |
| JP2008514577A5 (cg-RX-API-DMAC7.html) | ||
| RU2018107930A (ru) | Агонисты tlr4, их композиции и применение для лечения рака |